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Summary Glutathione levels were measured in 30 human lung cancer lines. Lower levels were detected in cell
lines derived from small cell lung cancer specimens compared to non-small cell lines (mean 42 vs.
130nmolmg-1 protein, P=0.005). However, no differences were detected between cell lines derived from
previously untreated patients, compared to those derived from patients who had received chemotherapy. Non-
small cell lines were found to have increased activity of 4 detoxification enzymes compared to small cell lines,
although these differences did not reach statistical significance: glutathione transferase activity (69 vs. 36 units,
P=0.137), glutathione reductase (139 vs. 82 units, P=0.05), y-glutamyl transpeptidase (9.39 vs. 3.03 units,
P=0.072) and superoxide dismutase (20 vs. 13.6 units, P=0.137). As the cell lines exhibit a similar
chemosensitivity pattern to that observed in clinical practice, these differences in glutathione and detoxifi-
cation enzyme levels may prove to be important indicators of intrinsic drug resistance often seen in patients
with non-small cell lung cancer.
The tripeptide glutathione (GSH) has been implicated in the
detoxification of a wide range of xenobiotics including many
of the currently used cytotoxic drugs (Arias & Jakoby, 1976;
Meister, 1981). Detoxification is generally achieved through
a substitution reaction with electrophilic compounds, often
catalysed by the glutathione-S-transferases [GST] (Jakoby &
Habig, 1980; Wolf et al., 1987). GSH detoxifies oxygen-
induced free radicals, a reaction catalysed by glutathione
peroxidase (GPX), and in addition, it is important in
transferring reducing equivalents in the cell. Modulation of
GSH levels by either lowering levels with buthionine sulfoxi-
mine (Dethmers & Meister, 1981) or raising levels with
oxothiazolidine-4-carboxylate (Williamson et al., 1982) or glu-
tathione esters (Anderson et al., 1985) changes the re-
sponse of cells to a number of cytotoxic drugs (Russo et al.,
1984; Russo & Mitchell, 1985) and ionising radiation
(Mitchell et al., 1983; Biaglow et al., 1983; Jensen &
Meister, 1983; Russo & Mitchell, 1984).
Lung cancer exhibits an interesting spectrum of drug and
radiation resistance, from small cell lung cancer (SCLC),
which is relatively sensitive on presentation, but which
exhibits an acquired resistance pattern on relapse, to the
intrinsically resistant non-small cell lung cancer (NSCLC)
(Bergsagel & Feld, 1986; Ruckdeschel et al., 1986). In view
of the importance of GSH and related enzymes in the
response of cells to both chemotherapy and radiation ther-
apy, measurements of these levels were performed on a panel
of human cell lines, including all of the major histological
sub-types of lung cancer.
Materials and methods
Cell lines
A panel of 30 human lung cancer cell lines was used. These
cell lines were derived from patients exhibiting a variety of
histological sub-types of lung cancer. Some of these patients
had received prior chemotherapy or radiotherapy. The
majority of SCLC lines grew as floating aggregates with the
exception of NCI-H841 which grew as a loosely adherent
monolayer. In contrast, all NSCLC lines grew as mono-
layers. Cell lines were grown in RPMI 1640 medium contain-
ing 10% (v/v) foetal calf serum with penicillin and
streptomycin. For experimental procedures cell lines were
maintained in exponential growth and had been refed 48 h
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prior to harvest. They were grown at 37°C in humidified
conditions in 7% CO2/93% air.
Glutathione assay
Cells were seeded in five 100mm Petri dishes at a cell density
to ensure that cells were in exponential growth phase at the
time of assay, with all cell lines refed with fresh medium 48h
prior to harvest. Cells were washed twice in ice-cold PBS,
with the cells from 3 plates lysed using 0.6% sulfosalicylic
acid at 4°C. The supernatant was then aspirated from each
plate and assayed individually for total GSH content as
previously described (Tietze, 1969). The remaining 2 dishes
were assayed for protein content using the method of
Bradford (1970).
Enzyme assays
Cells were washed twice in PBS, resuspended in 2ml
PBS with 0.005M EDTA, lysed by sonication and the super-
natant stored at -80°C prior to use, with all experiments
performed in triplicate.
Glutathione transferases
GST activity was measured using 1-chloro-2,4 dinitrobenzene
(CDNB) as substrate, as previously described by Habig et al.
(1974), monitoring spectrophotometric absorbance at
340nm.
Glutathione reductase
Glutathione reductase (GR) activity was measured as pre-
viously described (Massey & Williams, 1965), following
coupling of the substrate to GSH, with the reaction moni-
tored at a wavelength of 412nm.
y-glutamyl-transpeptidase
y-glutamyl transpeptidase activity was measured using L-y-
glutamyl-p-nitroanilide as substrate as described by Szasz
(1969), monitoring the reaction at an absorbance of 412nm.
Superoxide dismutases
Superoxide dismutase activity was estimated using pyra-
gallol, as previously described (Marklund & Marklund, 1974),
with inhibition of the autoxidation of pyragallol monitored
at a wavelength of 420nm.
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Table I Characteristics of lung cancer cell lines: C-SCLC=classic small cell lung cancer, V-SCLC=
variant small cell lung cancer. LCC=large cell anaplastic lung cancer. T=previous chemotherapy,
U/T=untreated patient, XRT=previous radiotherapy treatment status unknown. Chemosensitivity
expressed as the IC50 (± 1 s.d.), however where no bracket is shown this represents the results of one
experiment.
Lung cancer Histologic
cell line type
(a) Small cell lung cancer lines
NCI-H60 C-SCLC
NCI-H69 C-SCLC
NCI-H82 V-SCLC
NCI-H128 C-SCLC
NCI-H146 C-SCLC
NCI-H187 C-SCLC
NCI-H209 C-SCLC
NCI-H249 C-SCLC
NCI-N417 V-SCLC
NCI-H524 V-SCLC
NCI-H526 V-SCLC
NCI-H678 C-SCLC
NCI-H719 C-SCLC
NCI-H841 V-SCLC
NCI-H889 C-SCLC
(b) Non-small cell lung cancer lines
NCI-H23 Adenocarcinoma
NCI-H125 Adenocarcinoma
NCI-H157 LCC
NCI-H226 Squamous
NCI-H290 Mesothelioma
NCI-H322 Adenosquamous
NCI-H358 Adenocarcinoma
NCI-H460 LCC
NCI-H520 Squamous
NCI-H522 Adenocarcinoma
NCI-H596 Adenosquamous
NCI-H647 Adenosquamous
NCI-H661 LCC
A549 Adenocarcinoma
JMN Mesothelioma
Patient treatment
status
T
T
T
T
T
U/T
U/T
T
U/T
T
U/T
U/T
U/T
T
U/T
U/T
U/T
U/T
U/T
U/T
U/T
U/T
U/T
U/T
U/T
XRT
XRT
T
U/K
U/K
Chemosensitivity
IC50
Adriamycin Melphalan
(nM) (P1M)
171.0 (134)
127.0 (46)
94.0 (71)
110.0 (126)
144.0 (86)
25.5 (22)
24.8 (7.2)
127.0 (123)
12.9 (3)
15.8 (3.9)
37.0 (17)
61.0
10.1 (7.7)
231.0 (162)
13.4 (6.5)
38.7 (26)
216.0 (58)
238.0 (167)
221.0 (90)
26.8 (14)
173.0 (165)
85.0 (56)
16.5 (8)
411.0 (132)
197.0 (72)
813.0 (207)
115.0 (10)
130.0 (57)
57.7 (32)
40.2 (13)
2.8 (2.9)
10.1 (4)
7.9 (6.2)
20.8 (8)
13.8 (8)
1.8 (2)
0.2 (0.1)
10.2 (11)
0.8
2.8 (2.4)
0.1 (0)
6.3 (8)
0.1
84.0 (23)
3.6 (2)
8.7 (7)
8.2 (3)
105.0 (60)
56.3 (17)
3.7 (0.6)
75.5 (51)
31.0 (9)
1.6 (0.4)
23.3 (9)
30.3 (18)
60.7 (30)
55.3 (32)
20.4 (19)
11.4 (7)
3.3 (1)
Results
Details of the cell lines used are shown in Table I (Carney et
al., 1985, Gazdar et al., 1985). For the purpose of these
studies, the in vitro histology was used, with the in vivo
histology from the original biopsy different in only 3 cell
lines: NCI-H322, NCI-H358 and NCI-H522 (Carmichael et
al., 1988). In addition, this table shows the sensitivity of
these cell lines to 2 commonly used cytotoxic drugs, adria-
mycin and melphalan, whose effects are known to be
modulated by GSH (Green et al., 1984; Russo et al., 1984;
Russo & Mitchell, 1985). Chemosensitivity assays were per-
formed using the MTT assay (Carmichael et al., 1987), and
form part of a more detailed study of the chemosensitivity
profile of these cell lines (Carmichael et al., 1988). SCLC
lines derived from untreated patients were more sensitive to
adriamycin than cell lines established from previously treated
SCLC or NSCLC patients respectively: (mean IC50 26 vs.
127 vs. 185nM). Similar differences were observed for mel-
phalan (mean IC50 1.8 vs. 19.0 vs. 33.0pM).
GSH levels and levels of the various enzymes are listed in
Tables II and III for SCLC and NSCLC lines respectively.
Groups were compared and analysis performed using the
Kolmogorov-Smirnov test. In general, levels of all of these
parameters were lower for SCLC lines than for NSCLC
lines. The mean GSH level for the SCLC lines was
42nmolmg-1 protein compared to 130nmolmg-1 cytosolic
protein for NSCLC lines (P=0.005). Similarly, in NSCLC
lines enzyme activity was increased for all 4 enzymes com-
pared to SCLC lines although these changes did not achieve
statistical significance: mean GST 68 vs. 37 units (P=0.137),
GR 139 vs. 82 units (P=0.05), v-GT 9.39 vs. 3.03 units
(P=0.072) and SOD levels 20 vs. 13.6 units mg-1 protein
(P=0.137). Of interest, there were no differences in GSH or
enzyme activities comparing SCLC lines derived from
untreated patients with lines established from patients who
had previously received chemotherapy. No significant differ-
ence in any parameter was observed between histological
sub-types of NSCLC.
Discussion
Thirty human lung cancer cell lines were analysed for GSH
content, and for levels of a number of related detoxification
enzymes. These cell lines exhibited a similar histological
profile to that observed clinically, and their chemosensitivity
profile has been shown to closely resemble that seen in
clinical practice (Carmichael et al., 1988).
GSH levels were found to be significantly lower in SCLC
lines with no detectable difference between variant small cell
lines and cell lines exhibiting the classical phenotype (Carney
et al., 1985). Surprisingly, no differences in GSH levels were
detected comparing SCLC lines established from treated and
previously untreated patients despite the fact that differences
in chemosensitivity were maintained between the groups in
vitro. The lack of correlation between GSH levels and
treatment status is particularly surprising, in that many of
these patients had been heavily pretreated with classes of
cytotoxic agents which have been shown to interact with
GSH (Doroshow et al., 1980; Berrigan et al., 1982; Dulik et
al., 1986). However, it is possible that GSH levels decreased
on serial passage in tissue culture. Certainly, in some malig-
nant ascites samples obtained in this laboratory (JBM), GSH
levels had fallen to less than 30% of primary tumour levels
within 5 passages (unpublished data).GLUTATHIONE ACTIVITY IN HUMAN LUNG CANCER 439
Table II Glutathione levels and related enzyme activity of human small cell
lung cancer cell lines
Cell line
NCI-H187
NCI-H209
NCI-N417
NCI-H526
NCI-H678
NCI-H719
NCI-H889
NCI-H60
NCI-H69
NCI-H82
NCI-H128
NCI-H146
NCI-H249
NCI-H524
NCI-H841
GSH
41+9
56+7
24+0
54+ 15
32+ 10
54+20
66+20
43 +28
48+14
31+5
26+ 10
50+ 14
24+15
25+19
58+1
GST
44+30
48+41
4+2
107+85
41 +22
67+14
15+3
15+6
32+37
25+12
45+35
34+29
28+26
6+3
37+9
GR y-GT SOD
51 +30
67+20
102+ 17
106+43
115+38
72+69
92+17
57+26
108+43
83+ 59
50+35
83 +29
87+41
48+36
114+46
3.9+2.3
1.9+ 1.6
0.5+0.3
1.8+ 1.3
1.9+ 1.5
6.2+ 1.5
2.6+ 1.6
2.2+ 1.4
1.7+0.8
2.1+ 1.9
6.7+6.6
4.6+5.0
1.9+ 1.6
4.5+4.0
3.1 +2.7
15+ 11
10+7
8+3
21+ 11
17+ 10
16+0
13+ 15
15+ 17
10+3
10+8
32+28
10+7
8+5
9+2
8+1
GSH - Glutathione content - nmolmg-1 protein; GST - Glutathione
transferase activity - nmol CDNB conjugated min-1 mg prot-1; GR -
Glutathione reductase activity - nmol NADPH utilised min- mg prot- ; y-
GT - y-glutamyl transpeptidase activity - nmof L-y-glutamyl-p-nitroanilide
metabolised min 1 mg prot-1; SOD - Superoxide dismutase activity - 1
unit= Concentration of SOD causing 50% reduction in the autoxidation of
pyragallol. Levels represent the mean of 3 determinations+ 1 s.d.
Table III Glutathione levels and related enzyme activity of human non-small cell lung cancer
cell lines
Cell line GSH GST GR y-GT SOD
NCI-H23 103 +26 117+0 54+24 4.0+4.0 17+9
NCI-H125 100+33 43+22 129+52 5.5+2.9 14+9
NCI-H157 65+22 46+ 17 75+ 16 3.6+1.2 16+12
NCI-H226 210+51 39+37 70+8 2.7+2.1 27+ 15
NCI-H290 140+10 38+22 74+30 5.8+2.7 11+2
NCI-H322 150+27 38+ 18 126+74 6.0+8.0 25+26
NCI-H358 100+51 67+39 152+63 7.0+4.1 13+9
NCI-H460 220+90 43+19 251 +85 7.2+4.7 11+3
NCI-H520 160+61 232+ 177 139+53 2.5+1.0 23+11
NCI-H522 80+42 109+89 146+53 3.5+2.9 18+8
NCI-H596 140+70 16+14 267+200 6.7+4.3 49+36
NCI-H647 160+43 117+97 251 +53 65.6+35 46+39
NCI-H661 100+16 79+79 74+22 5.4+3.8 15+7
JMN 80+11 24+24 44+9 3.3+2.6 8+1
A549 140+37 24+16 235+144 12.1+4.3 10+8
GSH - Glutathione content - nmolmg-1 protein; GST - Glutathione transferase activity -
nmol CDNB conjugated min- 1 mg prot-1; GR - Glutathione reductase activity - nmol
NADPH utilised min-1 mg prot-1; y-GT - y-glutamyl transpeptidase activity - nmol L-y-
glutamyl-p-nitroanilide metabolised min-1 mg prot-1; SOD - Superoxide dismutase activity - I
unit=Concentration of SOD causing 50% reduction in the autoxidation of pyragallol. Levels
represent the mean of 3 determinations+ 1 s.d.
The difference in GSH levels between SCLC and NSCLC
cell lines is extremely interesting in view of the importance of
this tripeptide in the cellular response to cytotoxic drugs,
although probably of more importance is whether there are
similar differences between normal and neoplastic tissues. Of
interest, buthionine sulfoximine (Dethmers & Meister,
1981) is shortly to enter clinical trial in the USA, making
modulation of GSH levels a realistic possibility clinically.
Marked differences in enzyme activity were noted between
SCLC and NSCLC lines. Some cell lines exhibited very high
levels of one or more of these enzymes, but there was no
apparent correlation with histological type, although it
should be emphasised that numbers in these groups were
small.
Of particular interest were the 2 mesothelioma cell lines
which have previously been shown to be relatively sensitive
in vitro to a number of cytotoxic drugs (Carmichael et al.,
1988) and to radiation (Carmichael, unpublished), in con-
trast to clinical experience with this tumour type (Chahinian,
1982). No obvious difference in GSH levels was observed in
these cell lines compared to other NSCLC lines, although
GST and SOD activity were reduced in both lines.
GST activity was measured in this study, using CDNB as
substrate. However, it is known that these proteins exhibit
variable substrate specificity (Mannervik, 1985) and are
representative of a multigene family. An acidic transferase
has been implicated in the resistance associated with pre-
neoplasia (Kitahara & Satoh, 1983; Faber, 1984) and in
MCF 7 cells in vitro, that express the multidrug resistance
phenotype (Batist et al., 1986). In an attempt to identify a
resistance 'marker' for lung cancer, it is intended to extend
these studies to include an analysis of the GST isoenzyme
pattern of these cell lines. In addition, it is intended to
extend these studies to include an assessment of other
detoxification enzymes. In view of the multi-drug resistance
pattern exhibited by some of these lines (Bech-Hansen et al.,
1976). It is possible that differences in expression of multi-
drug resistance genes (Fojo et al., 1987) account for some of
the observed differences in chemosensitivity and this is
currently being assessed.
In a panel of 30 cell lines covering the major histological
sub-groups of lung cancer, significant differences were
observed in GSH levels and in the activity of a number of
detoxification enzymes. These differences were apparent in
cell types where drug resistance is considered intrinsic. In
contrast, in acquired drug resistance, such as in cell lines
derived from previously treated patients, these differences
were no longer apparent. Whether these differences are an in440 J. CARMICHAEL et al.
vitro artefact remains unanswered, although it should be
stressed that in the majority of in vitro derived resistance
models changes in these enzymes are frequently observed.
This cell line panel may prove to be a valuable tool for the
study of clinical drug resistance in lung cancer.
The opinions or assertions contained herein are the private views of
the authors and are not to be construed as offlcial or as reflecting
the views of the Department of the Navy or the Department of the
Defense.
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